Artemis Pharmaceuticals and Schering AG Cooperate in Mouse Genetics
Artemis Pharmaceuticals GmbH, Cologne and Schering AG, Berlin, have signed a cooperation agreement in mouse genetics and genomics. As part of this cooperation, Artemis will generate various genetically engineered mouse models for Schering. Schering will use these mice in its drug discovery research activities to identify novel compounds and therapies for the treatment of severe diseases in various indications in man.
The generation of the mouse models will be based on Artemis' proprietary ArteMice(TM) and ArteMice(TM) Conditional(TM) technologies. These allow the rapid, highly efficient and reproducible generation of complex genetically modified mice for use as highly relevant model systems in drug discovery research. In particular they allow the functional analysis of genes, in an in vivo setting, to determine the role such genes play in disease processes and disease therapy. The partners did not disclose financial details.
"We are particularly delighted about our future cooperation with Schering, one of the leading pharmaceutical companies world wide. It is scientifically and economically important for Artemis", said Professor Peter Stadler, Managing Director of Artemis. "The fact that Schering has joined our distinguished list of customers provides further evidence of the value of the ArteMice(TM) platform to pharmaceutical and biotechnological companies. An increasing number of companies are using ArteMice(TM) through collaborations with Artemis to increase the productivity of their drug discovery and development activities."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
